SCHEMBL5165673

SCHEMBL5165673

NCc1ccc2c3c(cccc13)CC2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.57
ALDH1A1 P00352 9/20 0.57
HPGD P15428 6/20 0.57
LMNA P02545 4/20 0.57
GAA P10253 3/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
MAPT P10636 2/20 0.57
HSD17B10 Q99714 3/20 0.44
CYP3A4 P08684 1/20 0.44
ALOX15 P16050 1/20 0.44
POLB P06746 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ATM Q13315 1/20 0.43
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
SCN2A Q99250 1/20 0.40
PNMT P11086 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5079010 0.85 KDM4E (0.53) KDM4EALDH1A1HPGDLMNAGAA
SCHEMBL13101720 0.82 ALDH1A1 (0.53) KDM4EALDH1A1HPGDLMNAGAA
SCHEMBL5376065 0.80 ALDH1A1 (0.53) KDM4EALDH1A1HPGDLMNAGAA
SCHEMBL20021168 0.78 PRKCI (0.37) KDM4EALDH1A1HPGDLMNAGAA
SCHEMBL29093412 0.77 KDM4E (0.48) KDM4EALDH1A1HPGDLMNAGAA
SCHEMBL20710887 0.76 LOXL2 (0.43) ALDH1A1HPGDMEN1KMT2AHSD17B10
SCHEMBL18826311 0.76 KDM4E (0.47) KDM4EALDH1A1HPGDLMNAGAA
SCHEMBL4813288 0.76 LMNA (0.49) KDM4EALDH1A1HPGDLMNAGAA
SCHEMBL1253705 0.76 ALDH1A1 (0.47) KDM4EALDH1A1HPGDLMNAGAA
SCHEMBL11805134 0.74 ALDH1A1 (0.50) KDM4EALDH1A1HPGDLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1533374-B Substitutled cyclohexane-1,4-diamine derivatives GRUENETHAL GMBH 2013-08-21 CN disclosed
US-7276518-B2 Substituted cyclohexane-1,4-diamine compounds GRUENENTHAL GMBH (DE) 2007-10-02 US disclosed
EP-1392641-B1 SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2007-04-11 EP disclosed
US-20040229872-A1 Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity GRUENENTHAL GMBH (DE) 2004-11-18 US disclosed
CN-1533374-A Substitutled cyclohexane-1,4-diamine derivatives 2004-09-29 CN disclosed
US-20040162287-A1 Substituted cyclohexane-1,4-diamine compounds GRUENENTHAL GMBH (DE) 2004-08-19 US disclosed
EP-1392641-A1 SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2004-03-03 EP disclosed
EP-1385493-A1 SUBSTITUTED CYCLOHEXAN-1,4-DIAMINE DERIVATIVES WITH CONSTIPATING AND PERIPHERAL ANALGESIC PROPERTIES Grünenthal GmbH (DE) 2004-02-04 EP disclosed
WO-2002090317-A1 SUBSTITUTED CYCLOHEXANE-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2002-11-14 WO disclosed
WO-2002089783-A1 SUBSTITUTED CYCLOHEXAN-1,4-DIAMINE DERIVATIVES WITH CONSTIPATING AND PERIPHERAL ANALGESIC PROPERTIES Grünenthal GmbH (DE) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162287-A1 Substituted cyclohexane-1,4-diamine compounds DPYD, DDC, QDPR KDM4E 381/4885ALDH1A1 365/4885HPGD 282/4885
US-20040229872-A1 Substituted cyclohexane-1,4-diamine compounds with anti-diarrhea and peripheral analgesic activity ARG1, CD2, PDCD1 KDM4E 1528/4885ALDH1A1 1067/4885HPGD 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.